Allarity Therapeutics, Inc. (ALLR) News
Track canonical SquawkNews coverage tagged to ALLR, Allarity Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Allarity Therapeutics Receives U.S. Patent And Trademark Office Patent For Its Drug Response Predictor Companion Diagnostic
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR ), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor
EQUITY | Jun 30, 2026, 12:04 PM UTC
M
Healthcare Stocks Move
Gainers Catheter Precision (AMEX: VTAK ) shares rose 78.2% to $1.55 during Monday's after-market session. The company's market cap stands at $2.2 million. Allarity Therapeutics (NASDAQ: ALLR ) stock increased by 8.08% to
EQUITY | Jun 22, 2026, 09:10 PM UTC